BiotechTube

APX005M + Pembrolizumab

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Jun 2, 2017 → Mar 10, 2025

NCT ID
NCT02706353

About APX005M + Pembrolizumab

APX005M + Pembrolizumab is a phase 1/2 stage product being developed by Pyxis Oncology for Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02706353. Target conditions include Melanoma.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)
✅dabrafenib + trametinibNovartisApproved
✅ZelborafRocheApproved
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02706353Phase 1/2Terminated

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
mRNA-4157 + PembrolizumabMerckPhase 2
39
AVT32-DRL_PB + KeytrudaDr. Reddy's LaboratoriesPhase 1
33
Binimetinib Oral TabletBiotrialPhase 1
15
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
32
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
FYB206 + KeytrudaFormycon AGPhase 1
23
PLX3397Daiichi SankyoPre-clinical
26
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
24
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
DS-8273a + NivolumabDaiichi SankyoPhase 1
29
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
42
CP-461Astellas PharmaPhase 2
27
YM155Astellas PharmaPhase 2
35
YM155 + DocetaxelAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
E7080EisaiPhase 1
29
lenvatinib + pembrolizumabEisaiPhase 2
35
MORAb-004 (monoclonal antibody)EisaiPhase 2
35